Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial

Παρόμοια τεκμήρια

• NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS
  ανά: Goodman, A, κ.ά.
  Έκδοση: (2009)
• A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
  ανά: Folegatti, P, κ.ά.
  Έκδοση: (2021)
• Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
  ανά: Folegatti, PM, κ.ά.
  Έκδοση: (2020)
• Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
  ανά: Folegatti, P, κ.ά.
  Έκδοση: (2019)
• A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
  ανά: Pedro M. Folegatti, κ.ά.
  Έκδοση: (2021-07-01)